Total Payments
$31,729
2024 Payments
$27.69
Companies
17
Transactions
164
Medicare Patients
1,517
Medicare Billing
$578,637
Payment Breakdown by Category
Other$27,360 (86.2%)
Food & Beverage$2,678 (8.4%)
Travel$1,510 (4.8%)
Consulting$150.00 (0.5%)
Education$31.78 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27,360 | 16 | 86.2% |
| Food and Beverage | $2,678 | 135 | 8.4% |
| Travel and Lodging | $1,510 | 10 | 4.8% |
| Consulting Fee | $150.00 | 1 | 0.5% |
| Education | $31.78 | 2 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $18,953 | 38 | $0 (2024) |
| Allergan, Inc. | $10,965 | 20 | $0 (2020) |
| Shire North American Group Inc | $345.80 | 20 | $0 (2019) |
| Otsuka America Pharmaceutical, Inc. | $341.32 | 22 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $327.54 | 20 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $167.27 | 13 | $0 (2018) |
| Alkermes, Inc. | $164.90 | 2 | $0 (2022) |
| Avanir Pharmaceuticals, Inc. | $133.37 | 8 | $0 (2020) |
| Takeda Pharmaceuticals America, Inc. | $118.01 | 7 | $0 (2017) |
| Teva Pharmaceuticals USA, Inc. | $54.17 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $27.69 | 2 | ABBVIE INC. ($27.69) |
| 2023 | $11,003 | 26 | ABBVIE INC. ($10,972) |
| 2022 | $1,355 | 7 | ABBVIE INC. ($1,328) |
| 2021 | $6,667 | 10 | AbbVie Inc. ($6,613) |
| 2020 | $6,889 | 17 | Allergan, Inc. ($6,768) |
| 2019 | $4,563 | 34 | Allergan Inc. ($4,125) |
| 2018 | $790.63 | 50 | Otsuka America Pharmaceutical, Inc. ($191.18) |
| 2017 | $435.20 | 18 | Alkermes, Inc. ($150.00) |
All Payment Transactions
164 individual payment records from CMS Open Payments — Page 2 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/27/2023 | ABBVIE INC. | VRAYLAR (Drug) | Travel and Lodging | In-kind items and services | $280.00 | General |
| Category: NEUROSCIENCE | ||||||
| 01/27/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: NEUROSCIENCE | ||||||
| 01/27/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.81 | General |
| Category: NEUROSCIENCE | ||||||
| 09/08/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.15 | General |
| Category: NEUROSCIENCE | ||||||
| 08/17/2022 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $11.86 | General |
| Category: NEUROSCIENCE | ||||||
| 06/22/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: NEUROSCIENCE | ||||||
| 06/01/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.73 | General |
| Category: NEUROSCIENCE | ||||||
| 05/11/2022 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA INITIO | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: CNS | ||||||
| 02/08/2022 | ABBVIE INC. | VRAYLAR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,275.00 | General |
| Category: NEUROSCIENCE | ||||||
| 02/02/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: NEUROSCIENCE | ||||||
| 12/01/2021 | AbbVie Inc. | VRAYLAR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,320.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/10/2021 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: NEUROSCIENCE | ||||||
| 09/22/2021 | Takeda Pharmaceuticals U.S.A., Inc. | VYVANSE (Drug) | Food and Beverage | In-kind items and services | $12.70 | General |
| Category: NEUROSCIENCE | ||||||
| 07/14/2021 | AbbVie Inc. | VRAYLAR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,320.00 | General |
| Category: NEUROSCIENCE | ||||||
| 07/14/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: NEUROSCIENCE | ||||||
| 06/02/2021 | AbbVie Inc. | VRAYLAR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,320.00 | General |
| Category: NEUROSCIENCE | ||||||
| 05/05/2021 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: NEUROSCIENCE | ||||||
| 03/24/2021 | AbbVie Inc. | VRAYLAR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,320.00 | General |
| Category: NEUROSCIENCE | ||||||
| 03/10/2021 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $12.80 | General |
| Category: NEUROSCIENCE | ||||||
| 03/03/2021 | AbbVie Inc. | VRAYLAR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,320.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2020 | Allergan, Inc. | VRAYLAR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,320.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/21/2020 | Allergan, Inc. | VRAYLAR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,320.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/21/2020 | Allergan, Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.91 | General |
| Category: NEUROSCIENCE | ||||||
| 10/13/2020 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: NEUROSCIENCE | ||||||
| 10/13/2020 | Allergan, Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $3.38 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 345 | 1,934 | $237,918 | $138,540 |
| 2022 | 6 | 362 | 2,054 | $252,252 | $154,175 |
| 2021 | 5 | 381 | 1,959 | $241,618 | $151,512 |
| 2020 | 7 | 429 | 1,955 | $218,742 | $134,410 |
Total Patients
1,517
Total Services
7,902
Medicare Billing
$578,637
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 104 | 858 | $107,030 | $67,104 | 62.7% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2023 | 103 | 725 | $101,523 | $54,003 | 53.2% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 64 | 160 | $15,229 | $9,354 | 61.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 33 | $5,920 | $3,565 | 60.2% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2023 | 18 | 18 | $4,380 | $2,743 | 62.6% |
| 90785 | Psychiatric services complicated by communication factor | Office | 2023 | 30 | 140 | $3,835 | $1,771 | 46.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 103 | 880 | $109,630 | $71,729 | 65.4% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2022 | 102 | 759 | $106,278 | $58,763 | 55.3% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 73 | 191 | $18,089 | $11,849 | 65.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 43 | 68 | $12,080 | $7,901 | 65.4% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 12 | 12 | $2,921 | $2,082 | 71.3% |
| 90785 | Psychiatric services complicated by communication factor | Office | 2022 | 29 | 144 | $3,255 | $1,851 | 56.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 104 | 777 | $95,506 | $64,285 | 67.3% |
| 90836 | Psychotherapy with evaluation and management visit, 45 minutes | Office | 2021 | 100 | 684 | $95,076 | $53,564 | 56.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 66 | 149 | $26,082 | $17,564 | 67.3% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 82 | 236 | $22,334 | $14,614 | 65.4% |
| 90785 | Interactive complexity | Office | 2021 | 29 | 113 | $2,620 | $1,485 | 56.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 104 | 796 | $87,902 | $53,343 | 60.7% |
| 90836 | Psychotherapy, 45 minutes | Office | 2020 | 100 | 584 | $73,898 | $46,234 | 62.6% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 98 | 320 | $30,142 | $20,018 | 66.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 65 | 110 | $18,466 | $10,266 | 55.6% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 15 | 15 | $3,270 | $1,659 | 50.7% |
| 90785 | Interactive complexity | Office | 2020 | 36 | 119 | $2,785 | $1,600 | 57.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2020 | 11 | 11 | $2,279 | $1,291 | 56.6% |
About Dr. Mark Gurtovy, M.D
Dr. Mark Gurtovy, M.D is a Psychiatry healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053332072.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Gurtovy, M.D has received a total of $31,729 in payments from pharmaceutical and medical device companies, with $27.69 received in 2024. These payments were reported across 164 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($27,360).
As a Medicare-enrolled provider, Gurtovy has provided services to 1,517 Medicare beneficiaries, totaling 7,902 services with total Medicare billing of $578,637. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Other Specialties Psychiatry
- Location Brooklyn, NY
- Active Since 07/23/2006
- Last Updated 07/19/2010
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1053332072
Products in Payments
- VRAYLAR (Drug) $29,906
- REXULTI (Drug) $350.35
- Trintellix (Drug) $304.97
- VYVANSE (Drug) $290.70
- LATUDA (Drug) $167.27
- NUEDEXTA (Drug) $133.37
- TRINTELLIX (Drug) $113.11
- MYDAYIS (Drug) $54.37
- AUSTEDO (Drug) $54.17
- INGREZZA (Drug) $31.85
- SPRAVATO (Drug) $19.02
- WELLBUTRIN (Drug) $18.66
- ARISTADA (Drug) $14.90
- ABILIFY MAINTENA (Drug) $14.83
- Entyvio (Biological) $14.77
- LINZESS (Drug) $13.86
- JANUVIA (Drug) $13.67
- NATPARA (PARATHYROID HORMONE) (Drug) $13.43
- XARELTO (Drug) $13.00
- Aimovig (Biological) $12.50
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Brooklyn
Dr. Mark Owens, Do, DO
Psychiatry — Payments: $502,442
Psychiatry $502,442
Dr. Nancy Abdel-Wahab, M.d, M.D
Psychiatry — Payments: $194,999
Psychiatry $194,999
Louis Belzie, Md, Phd, MD, PHD
Psychiatry — Payments: $178,082
Psychiatry $178,082
Alexander Pinkusovich, Md, MD
Psychiatry — Payments: $111,246
Psychiatry $111,246
Thresiamma Nidhiry, Md, MD
Psychiatry — Payments: $27,833
Psychiatry $27,833
Dr. Irina Kiblitsky, M.d, M.D
Psychiatry — Payments: $22,079
Psychiatry $22,079